Abstract
Introduction

Diseases caused by trypanosomatids constitute a substantial health and socioeconomic problem in several countries, mainly in the Americas, sub-Saharan Africa and tropical and subtropical belt regions. In particular, Chagas' disease, (caused by Trypanosoma cruzi) affects 8 to 10 million people in the Americas, with an additional 40 million people at risk (www.who.int/tdr). T. cruzi has a complex life cycle involving a reduviid insect vector and a mammalian host (Fig. 1). Insect vectors become infected when they bite an infected mammal that has trypomastigote forms of the parasite circulating in its bloodstream. Trypomastigotes, infective non-dividing forms, are ingested with the blood; in the insect's digestive tube, they differentiate into dividing and non-infective epimastigote forms. In the terminal portion of the digestive tube, epimastigotes differentiate into metacyclic trypomastigotes, which are eliminated in faeces and deposited on mammals' skin while the triatomine bug bites and feeds. Trypomastigotes enter the body and invade host cells; they differentiate into dividing amastigote forms and after proliferating, differentiate into trypomastigotes, passing through a transient epimastigote-like stage. Finally, the trypomastigotes lyse host cells and are released into the extracellular medium, where they can invade other cells or the bloodstream, becoming capable of invading other tissues or a noninfected reduviid insect, thus completing the cycle
. In some cases, specific symptoms such as lymphadenopathy and splenomegaly, myalgia, malaise, muscle pains, sweating, hepatosplenomegaly or heart failure from myocarditis or pericardial effusion may be present. Less often, meningoencephalitis can occur, which can lead to death [2] . The chronic phase, in principle, can last for the patient's entire lifetime [3] [3] . The digestive form consists of two syndromes: megaesophagus, leading to dysphagia and regurgitation, and megacolon, leading to severe constipation and faecal retention [4] . In immunocompromised patients, severe compromise of the central nervous system has been also reported [5] [6] . The cysteine proteinases of T. cruzi, which participate in cellular processes such as energy metabolism, differentiation, host cell invasion and evasion of the immune system, have been validated as drug targets [8] . In particular, the use of synthetic inhibitors such as vinyl sulfone-derivatized dipeptides has shown promising results in vivo [9, 10] . In addition, sterol and polyisoprenoid biosynthesis pathways provide promising targets, because ergosterol (rather than cholesterol) is the main sterol in T. cruzi membranes [11] . Specific inhibitors such as azole derivatives [12] and bisphosphonates [13, 14] have been tested in vitro or in vivo. Inhibitors of T. cruzi specific enzymes such as trypanothione reductase [15] , arginine kinase [16] and proline racemase [17] have shown promising trypanocidal activities. It was recently shown that proline transporters could also be relevant targets [18] . Allopurinol, an inhibitor of purine (hypoxanthine/guanine)-phosphoribosyl-transferase, has been proposed for treating T. cruzi reactivation infection in patients after heart transplantation [19] . Inhibitors of topoisomerases I and II [20, 21] [49] . 
Chagas' disease
Chagas' disease presents mainly as two clinical phases in human beings: acute and chronic. The acute phase happens shortly after infection, beginning when the parasite enters the mammalian host. It is either largely asymptomatic or accompanied by non-specific symptoms such as fever and headache. It is characterized by an absence of antibodies and, in most patients, a conspicuous para-
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The immune response against T. cruzi is also influenced by NK, NK T and regulatory T cells (T reg). The relevance of NK cells in acute T. cruzi infection was demonstrated when normal, NKdepleted mice showed a significant increase in parasitemia and
Immune response in the treatment of chagasic infection
As previously mentioned, the resistance developed during experimental Chagas' disease depends on innate immune responses as well as on a prevalent Th1 response at the beginning of infection.
In addition, the antibodies produced by a Th2 response can contribute to the control of in vivo parasite replication (schematized in Fig. 3 [117] .
These properties of BZL have been further demonstrated by its ability to increase survival and decrease serum levels of IL-6 and TNF-␣ in C57BL/6 mice challenged systemically with LPS [118]. In an infectious-based situation of systemic inflammatory response (cecal ligation and puncture, CLP), mice treated with BZL had an increased survival rate and a significant reduction of TNF-␣ levels and bacteremia 24 hrs after CLP [119]. Such beneficial properties may broaden the potential use of BZL in hyperacute cases where inflammatory responses become harmful.
There are limited data concerning the effects of NF on immune responses, mainly because treatment with this drug was discontinued in the 1980s. At the experimental level, no gross changes in cell-mediated immunity were recorded in NF-treated mice [120] . However, an impaired PPD skin reaction was seen in guinea pigs when this compound was administered [121] . From [123, 124] . Treatment of the symptomatic complications of Chagas' disease, mainly related to heart failure, is also effective in improving quality of life. Heart transplantation [125] and cellular therapy with stem cells [126] 
